Ruxolitinib Combo Shows Potential in Post-MPN AML, But Unmet Need Remains
Published: Wednesday, Mar 18, 2020
Prithviraj Bose, MD
The combination of ruxolitinib (Jakafi) and decitabine is a viable alternative to intensive chemotherapy with comparable response rates in patients with post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML), according to findings from a phase I/II study.
... to read the full story